European markets opened higher on Tuesday, in a shortened trading session for Christmas Eve. At the opening bell, the ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...

The study met its main goal, but those watching closely had hoped for an average result of at least 25% weight loss.

Shares of Novo Nordisk (CSE: NOVOb) continued their upward momentum on Tuesday, rising over 5%, following gains on Monday.

The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.

FRANKFURT: Europe’s STOXX 600 closed slightly higher at the start of a holiday-shortened week, as a spike in Novo Nordisk ...

EUROPE’S Stoxx 600 closed slightly higher at the start of a holiday-shortened week, as a spike in Novo Nordisk shares boosted ...

Health insurers such as UnitedHealth Group and Cigna also recovered some of their recent losses following public controversy about industry practices in the wake of the assassination of UnitedHealth ...

Europe's STOXX 600 ended the day slightly up, driven by a surge in Novo Nordisk shares that helped the healthcare sector. Low trading volumes characterized the day due to holiday anticipation, while ...

European stocks turned in a mixed performance on Monday as investors, digesting some economic data from the region, largely made ...